Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr 20;22(4):690-9.
doi: 10.1021/bc1004526. Epub 2011 Apr 1.

Synthesis, characterization, and in vitro transfection activity of charge-reversal amphiphiles for DNA delivery

Xiao-Xiang Zhang  1 , Carla A H Prata, Jason A Berlin, Thomas J McIntosh, Philippe Barthelemy, Mark W Grinstaff
Affiliations

Synthesis, characterization, and in vitro transfection activity of charge-reversal amphiphiles for DNA delivery

Xiao-Xiang Zhang et al. Bioconjug Chem. .

Abstract

A series of charge-reversal lipids were synthesized that possess varying chain lengths and end functionalities. These lipids were designed to bind and then release DNA based on a change in electrostatic interaction with DNA. Specifically, a cleavable ester linkage is located at the ends of the hydrocarbon chains. The DNA release from the amphiphile was tuned by altering the length and position of the ester linkage in the hydrophobic chains of the lipids through the preparation of five new amphiphiles. The amphiphiles and corresponding lipoplexes were characterized by DSC, TEM, and X-ray, as well as evaluated for DNA binding and DNA transfection. For one specific charge-reversal lipid, stable lipoplexes of approximately 550 nm were formed, and with this amphiphile, effective in vitro DNA transfection activities was observed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures of several common cationic lipids.
Figure 2
Figure 2
Charge-reversal or charge- switchable effect of the amphiphiles.
Figure 3
Figure 3
Structures of the charge-reversal amphiphiles under investigation for gene delivery.
Figure 4
Figure 4
(top) Fluorescence intensity as a function of amphiphile/DNA charge ratio. (bottom) The fluorescence intensity as a function of amphiphile/DNA charge ratio for amphiphiles 1, 6-10, and DOTAP. N=3 Avg ± SD
Figure 5
Figure 5
Fluorescence intensity as a function of amphiphile/DNA charge ratio in function of the pH. N=3 Avg ± SD
Figure 6
Figure 6
Ethidium bromide intercalation assay showing the fluorescence intensity as a function of time in the presence of a porcine liver esterase (1000 units/mL). N=3 Avg ± SD
Figure 7
Figure 7
Ethidium bromide intercalation assay showing the fluorescence intensity as a function of time in the presence of a porcine liver esterase. N = 3 Avg ± SD
Figure 8
Figure 8
Transfection efficiency of the different amphiphiles in CHO cells. N=3 Avg ± SD
Figure 9
Figure 9
Photograph of β-galactosidase transfected cells using amphiphile 1 at low and high magnification. Dark blue stain represents B-gal expression.
Figure 10
Figure 10
Cytotoxicity of the different lipids in CHO cells. N=3 Avg ± SD
Figure 11
Figure 11
Transfection efficiency of amphiphile 1 with HEK293 and K562 cell lines. N=3 Avg ± SD. First data set with 1 is at 15:1 and the second data set is at 45:1 charge ratio.
Figure 12
Figure 12
TEM micrographs of amphiphile 1 in aqueous solution, negative staining with ammonium molybdate 1% in water.
Figure 13
Figure 13
Flow cytometry histogram for CHO cells transfected with rhodamine-labeled DNA using either 1 (blue) or 6 (red). Negative control (black).
None
Scheme 1
Synthesis of the charge-reversal amphiphiles.
See this image and copyright information in PMC

References

    1. Deregowski P, Canalis E. Gene delivery by retroviruses. Methods in Molecular Biology. 2008;455:157–162. - PubMed
    1. Flotte TR. Gene therapy progress and prospects: Recombinant adeno-associated virus (rAAV) vectors. Gene Therapy. 2004;11:805–810. - PubMed
    1. Lundstrom K. Gene therapy applications of viral vectors. Technology in Cancer Research & Treatment. 2004;3:467–477. - PubMed
    1. Flotte TR. Gene therapy: The first two decades and the current state-of-the-art. J Cellular Physiology. 2007;213:301–305. - PubMed
    1. Ozawa K. Gene therapy using AAV vectors. Drug Del System. 2007;22:643–650.

Publication types